Last checked at 18 May 2017 07:00
For immediate release 7.00am: 18 May 2017
HVIVO PLC
("hVIVO" or the "Company")
Award of Deferred Bonus Share Options
hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, announces that on 17 May 2017 it awarded the following options over ordinary shares of 5.0 pence each in the Company to persons discharging managerial responsibilities ("PDMR"):
PDMR | Total no. of shares under award | Type of awards |
Kym Denny | 32,813 | Deferred Bonus Award |
Graham Yeatman | 26,250 | Deferred Bonus Award |
The deferred bonus share options will normally vest on the second anniversary of date of grant (17 May 2019), subject to continued employment but no other performance condition. The deferred bonus awards represent 50% of 2016 bonus awarded by the Remuneration Committee, with the other 50% paid as cash.
The exercise price payable per share is the nominal price of a share (currently 5 pence). Vested options will be able to be exercised up to the tenth anniversary of date of grant.
Details of the full notifications received by the Company are set out below:
1 | Details of the person discharging managerial responsibilities / person closely associated | ||||||||||
a) | Name | Kym Denny and Graham Yeatman | |||||||||
2 | Reason for Notification | ||||||||||
a) | Position/status | Chief Executive Officer and Chief Financial & Business Officer | |||||||||
b) | Initial notification/Amendment | Initial notification | |||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
a) | Name | hVIVO PLC | |||||||||
b) | Legal Entity Identifier | 2138003PFXHA22YPN676 | |||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 5 pence each
GB00B6ZM0X53 | |||||||||
b) | Nature of the transaction | Grant of deferred bonus share options as follows:
The deferred bonus share options will normally vest on the second anniversary of date of grant (17 May 2019), subject to continued employment but no other performance condition.
The exercise price payable per share is the nominal price of a share (currently 5 pence).
Vested options will be able to be exercised up to the tenth anniversary of date of grant.
| |||||||||
c) | Currency | GBP | |||||||||
d) | Price(s) and volume(s) |
| |||||||||
e) | Aggregated information - Aggregated volume - Price |
59,063 shares 5.0 pence | |||||||||
f) | Date of the transaction | 17 May 2017 | |||||||||
g) | Place of the transaction | Outside a trading venue | |||||||||
For further information please contact:
hVIVO plc | +44 207 756 1300 |
Kym Denny (Chief Executive Officer) | |
Graham Yeatman (Chief Financial & Business Officer) | |
Numis Securities Limited | +44 207 260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) | |
James Black / Michael Burke (Corporate Broking) | |
FTI Consulting | |
Simon Conway / Victoria Foster Mitchell (UK) | +44 203 727 1000 |
John Capodanno / Evan Smith (US) | +1 212 850 5705 |
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.